Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 5/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6741795 | 0.82 | NPY5R (0.45) | FFAR1SLC6A9CNR2ABCB1KLK7 | |
| SCHEMBL15809469 | 0.79 | SLC6A9 (0.52) | SLC6A9SLC6A4 | |
| SCHEMBL15809472 | 0.79 | SLC6A9 (0.52) | SLC6A9SLC6A4 | |
| SCHEMBL8332028 | 0.77 | AKR1B1 (0.52) | FFAR1SRD5A2AKR1B1 | |
| SCHEMBL7828941 | 0.77 | L3MBTL1 (0.41) | TSHR | |
| SCHEMBL6239019 | 0.76 | SLC6A9 (0.47) | FFAR1SLC6A9SRD5A2ALOX15AKR1B1 | |
| SCHEMBL32660768 | 0.75 | SLC6A2 (0.58) | FFAR1SLC6A9SRD5A2ALOX15AKR1B1 | |
| SCHEMBL21554546 | 0.74 | CA2 (0.50) | FFAR1AKR1B1ABCC4LMNAGAA | |
| SCHEMBL32660760 | 0.74 | SLC6A4 (0.69) | ALOX15LMNATSHRHTTSLC6A4 | |
| SCHEMBL32660765 | 0.74 | SLC6A4 (0.69) | ALOX15LMNATSHRHTTSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6689771-B2 | TREATMENT OF RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTITIS, GINGIVITIS, CORNEAL ULCERATION, SOLID TUMOR GROWTH | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-02-10 | — | — | US | disclosed |
| US-20030032803-A1 | Novel amide derivatives as inhibitors of matrix metalloproteinases, TNF-alpha, and aggrecanase | DUAN JINGWU (US) | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032803-A1 | Novel amide derivatives as inhibitors of matrix metalloproteinases, TNF-alpha, and aggrecanase | TNF, MMP1, ADAMTS1 | FFAR1 2386/4885SLC6A9 2628/4885SRD5A2 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.